Frontier Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Frontier Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-382,648	Closed	-$3.67M	–	270
2022 Q3	$3.67M	Buy	382,648 +65,259	+21%	+$753K	0.04%	248
2022 Q2	$3.5M	Sell	317,389 -111,869	-26%	-$1.47M	0.04%	257
2022 Q1	$7.15M	Sell	429,258 -108,039	-20%	-$1.67M	0.06%	232
2021 Q4	$10.3M	Sell	537,297 -139,645	-21%	-$3.07M	0.08%	221
2021 Q3	$16.7M	Sell	676,942 -337,871	-33%	-$7.96M	0.13%	186
2021 Q2	$26.4M	Buy	+1,014,813	New	+$26.4M	0.19%	165

Other funds holding IOVA

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Frontier Capital Management's IOVA Position: Q4 2022 in Review

Frontier Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2022, closing a stake of 382,648 shares — an estimated $3.67M sold.

Frontier Capital Management first reported a position in IOVA in Q2 2021 and held it in 6 quarters. The position peaked at $26.4M in Q2 2021. 218 funds tracked by Wall St. Rank hold IOVA as of Q4 2022.

Frontier Capital Management reported no remaining Iovance Biotherapeutics position as of Q4 2022 after selling out during the quarter.
Frontier Capital Management sold 382,648 Iovance Biotherapeutics shares in Q4 2022, an estimated $3.67M.
Frontier Capital Management first reported a position in Iovance Biotherapeutics in Q2 2021 and held it in 6 quarters.
Frontier Capital Management's Iovance Biotherapeutics position peaked at $26.4M in Q2 2021.
218 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2022.

Based on Frontier Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.